BACKGROUND: @entity66864 ( @entity66864 ) is an excellent transporter for @entity2449 , which is used as first-line therapy for @entity2175 ( @entity2175 ). @entity66864 genetic variants may influence the clinical response to @entity2449 . This study aimed to determine the genotype and allele frequency of @entity66864 @entity69148 ( @entity69149 ) variant and its role in the glycemic response to @entity2449 in @entity1 with newly diagnosed @entity2175 . MATERIALS AND METHODS: Based on the response to @entity2449 , 150 @entity1 were classified into two groups: Sixty-nine responders (decrease in glycated hemoglobin [HbA1c] values by more than 1% from the baseline) and 81 nonresponders (decrease in @entity4051 c values <1% from the baseline). HbA1c levels were determined by chromatography. The variant @entity66864 @entity69148 was genotyped using polymerase chain reaction - based restriction fragment length polymorphism. RESULTS: The genotypes frequencies were 51.3% GG, 36% AG, and 12.7% AA. Allele frequency of major allele (G) and minor allele (A) in @entity66864 @entity69148 variant was found to be 0.69 and 0.31, respectively. Fasting @entity413 , HbA1c, body mass index, and lipid profile in both GG genotypes and GA + AA group decreased significantly after 3 months of @entity2449 therapy compared with baseline (P < 0.05). In both responders and nonresponders, HbA1c and fasting @entity413 levels were lower in @entity1 with the GA + AA genotype than in those with the GG genotype; however, the differences were not statistically significant (P > 0.05). CONCLUSION: The A allele frequency (which may be a protective allele against @entity301 ) in the Iranian @entity6 @entity1 was lower than Iranian, Caucasian and Japanese healthy populations. @entity2449 is useful in improving the lipid profile, in addition to its impacts in glycemic control, and these effects are regardless of @entity66864 @entity69148 variant.

Allele frequency and genotype distribution of a common variant in the 3  -untranslated region of the SLC22A3 gene in XXXX with @entity2175 : Association with response to @entity2449 .

@entity2175 :: ('MESH:D003924', 'Disease') :: ['type 2 diabetes', 'T2D'] @entity1 :: ('9606', 'Species') :: ['patients'] @entity4051 :: ('3039', 'Gene') :: ['HbA1'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetic'] @entity301 :: ('MESH:D003327', 'Disease') :: ['coronary heart disease'] @entity66864 :: ('100049579', 'Gene') :: ['Organic cation transporter 3', 'OCT3'] @entity2449 :: ('MESH:D008687', 'Chemical') :: ['Metformin', 'metformin'] @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose'] @entity69148 :: ('c|SUB|G|-564|A', 'DNAMutation') :: ['-564G>A'] @entity69149 :: ('rs3088442', 'SNP') :: ['rs3088442']
@entity1 :: (9606,Species) :: ['patients']
